Results 211 to 220 of about 1,506,798 (328)
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
Stabilising spatiotemporal dynamics of mussel-algae coupled map lattices model via proportional-differential control. [PDF]
Zhu Y +4 more
europepmc +1 more source
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha +10 more
wiley +1 more source
On the Mode Localization Between Two Unidentical Resonators with Different Bending Modes for Acceleration Sensing. [PDF]
Yang B, Lyu M, Zhao J, Kacem N.
europepmc +1 more source
A coupled fixed point theorem and application to fractional hybrid differential problems
Tahereh Bashiri +2 more
openalex +1 more source
On certain applications via coupled fixed point theorems in partially ordered Gb-metric spaces
openalex +1 more source
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
Implementation of a Low-Cost Navigation System Using Data Fusion of a Micro-Electro-Mechanical System Inertial Sensor and an Ultra Short Baseline on a Microcontroller. [PDF]
Winkler J, Badri-Hoeher S.
europepmc +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source

